

Effectiveness of XBB.1.5 monovalent COVID-19 vaccines during a period of XBB.1.5 dominance in EU/EEA countries, October to November 2023

Susana Monge¹, James Humphreys², Nathalie Nicolay³, Toon Braeye⁴, Izaak Van Evercooren⁴, Christian Holm Hansen⁵, Hanne-Dorthe Emborg⁵, Chiara Sacco⁶, Alberto Mateo Urdiales⁶, Jesus Castilla⁷, Iván Martínez-Baz⁷, Brechje de Gier⁸, Susan Hahné⁸, Hinta Meijerink⁹, Anja Bråthen Kristoffersen⁹, Ausenda Machado¹⁰, Patricia Soares¹⁰, Anthony Nardone², Sabrina Bacci³, Esther Kissling², and Baltazar Nunes²

¹Instituto de Salud Carlos III

²Epiconcept SAS

³European Centre for Disease Prevention and Control

⁴Sciensano

⁵Statens Serum Institut

⁶Istituto Superiore di Sanita

⁷Instituto de Salud Publica y Laboral de Navarra

⁸Rijksinstituut voor Volksgezondheid en Milieu

⁹Folkehelseinstituttet

¹⁰Instituto Nacional de Saude Doutor Ricardo Jorge

May 02, 2024

Abstract

Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in [?]65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted Hazard Ratios and derive VE. VE for COVID-10 hospitalisation and death was, respectively, 67% (95%CI: 60-72) and 68% (95%CI: 44-82) in 65–79-year-olds, and 64% (95%CI: 49-75) and 74% (95%CI: 56-85) in [?]80-year-olds. Results indicate that periodic vaccination of individuals [?]65 years has an ongoing benefit, and support the current vaccination strategies in the EU/EEA.

Hosted file

Main_document.docx available at <https://authorea.com/users/462723/articles/897192-effectiveness-of-xbb-1-5-monovalent-covid-19-vaccines-during-a-period-of-xbb-1-5-dominance-in-eu-eea-countries-october-to-november-2023>